SAN DIEGO & SHANGHAI–(BUSINESS WIRE)– Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical […]
Other News
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results
ATLANTA, Feb. 1, 2024 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes. On…
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024. “We delivered total revenue […]
SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation
SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Jan. 31, 2024 /PRNewswire/ — SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disorders, announced…
GE HealthCare Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation
Latest digital platform provides key advancements to help maintain high signal fidelity while reducing environmental noise Forward-looking platform designed to help enable path to new technologies in the electrophysiology (EP) lab Chicago, IL – January 31, 2024 – GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka […]
Genomics plc publishes clinical trial results demonstrating successful integration and clinical utility of integrated risk scores combining polygenic and clinical risk of cardiovascular disease in NHS primary care
Published in the European Journal of Preventive Cardiology, the paper demonstrates that polygenic risk score information can be successfully integrated into current general practitioner (GP) clinical practice for the prevention of cardiovascular disease The paper also demonstrates that…
BioSig Announces Reverse Stock Split
Westport, CT, Jan. 31, 2024 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it intends to effect a reverse stock split of its common stock at a ratio […]
New Philips Mini TEE ultrasound transducer helps improve cardiac care for more patients
January 31, 2023 Latest innovation has the potential to reduce anesthesia during minimally invasive procedures [1] As a pioneer and leading innovator in cardiac ultrasound, Philips has developed the smaller X11- 4t Mini 3D TEE transducer to serve more patients with this valuable imaging tool, from pediatric patients to older […]
Care Access Becomes Newest Member of the National Lipid Association Industry Council, Joining Novartis, Amgen, and Other Cardiovascular Health Leaders
BOSTON–(BUSINESS WIRE)–Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council. The collaboration aims to enable more community-based lipidologists to participate in clinical research and create access to cardiometabolic trials for their patients. “Partnering with the NLA […]
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
HAYWARD, Calif.–(BUSINESS WIRE)– Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial fibrillation, today announced that its nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium in […]
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet